

## 2bPrecise Collaborates with Mayo Clinic to Develop and Apply Genomics-Based Clinical Decision Support Tools

June 5, 2017 June 05, 2017 09:00 AM Eastern Daylight Time

PITTSBURGH--(<u>BUSINESS WIRE</u>)--2bPrecise, LLC, an EHR-agnostic, cloud-based precision medicine platform, today announced a technology license agreement with Mayo Clinic as well as a collaboration to develop and research genomics-based care protocols. Leveraging the unique functionality of the 2bPrecise platform and Mayo Clinic's know-how and electronic phenotyping algorithms, 2bPrecise will incorporate these new clinical protocols, and apply them in research to measure outcomes in patients with cardiovascular genetic disease.

2bPrecise selected Mayo Clinic for this work because of their strong subject matter expertise and work in the area of clinical genomics, specifically their research in familial hypercholesterolemia (FH), and for their desire to share their care algorithms more broadly with the medical community.

"Mayo Clinic has a very robust genomics research discipline," says Assaf Halevy, founder and CEO of 2bPrecise. "The wealth of both genetic research and clinical data within the clinic is staggering. This is why we are so excited to collaborate with premier organizations like Mayo Clinic to advance genomic science and help make it clinically actionable."

The 2bPrecise platform harmonizes clinical and genomic information to extract patient-specific insights and present them in an actionable way to the clinician, within their current EHR workflow, overlaying knowledge sources to guide and enable clinical genomics at point of care. The two organizations will begin their collaboration by bringing Mayo Clinic's algorithm for FH into the 2bPrecise platform to derive insights from combined clinical and genomic research data. The collaboration aims to empower clinical researchers with the ability to test and validate new protocols based on clinical-genomic insights, with the ultimate goal of making these protocols available for optimized decision-making at the point of care.

Mayo Clinic has a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

## About 2bPrecise

2bPrecise harnesses the power of genomics and precision medicine in an effort to precisely predict and efficiently treat each individual patient. 2bPrecise's EHR-agnostic, cloud-based platform captures and stores genomic data and harmonizes it with research knowledge and clinical information. The resulting actionable insights are then pushed into a provider's existing clinical workflow to facilitate decision-making at the point of care. Learn more at www.2bPrecisehealth.com.

## Contacts

Media: Aria Marketing for 2bPrecise Danielle Johns, 617-332-9999 x241 diohns@ariamarketing.com